CXCL9 and melanoma: The expression of CXCL9 was induced only by DAC treatment in 20% (2/10) chemokine-negative melanoma cells, while it was up-regulated (FC ≥2) by treatment with guadecitabine and DAC in 25% (1/4) and 75% (3/4) chemokine-positive melanoma cells, respectively, compared to 0% in AZA-treated cells (Supplementary Table 16).